Division of Gastroenterology and Hepatology, Stanford University School of Medicine and Palo Alto Veterans Administration Medical Center, CCSR Building, Room 3115, 269 Campus Drive, Palo Alto, CA 94305-5187, USA
Hepatitis C virus (HCV) is a significant cause of morbidity and mortality, infecting over 150 million people worldwide [1,2]. In spite of recent progress, current therapies remain inadequate for the majority of patients [3-5]. The study of HCV molecular virology is providing an increasing number of new anti-HCV targets. These are being translated into the development of new drugs that offer the prospect of more effective antiviral therapies. This article provides a concise review and update of the major highlights in these efforts.
Was this article helpful?